Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Terence W Friedlander

13PUBLICATIONS
114CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersPacific Peoples theory of change models for healthCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

Sort by Publication Date:
|Feb 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.

Matthew D Galsky, Karen A Autio, Christopher R Cabanski

|Jan 26, 2024
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.

Hewitt Chang, Jaqueline Marquez, Brandon K Chen

|Jan 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes

|Aug 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).

Alexandra Drakaki, Thomas Powles, Aristotelis Bamias

|Jun 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak

|Jun 01, 2023
Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study.

Elizabeth Y Wang, Hala T Borno, Samuel L Washington Iii

Pageof 3

Frequent Collaborators

3 joint publications

Lawrence Fong

3 joint publications

Matthew I Milowsky

3 joint publications

Christopher J Hoimes

3 joint publications

Daniel P Petrylak

3 joint publications

Rana R McKay

3 joint publications

Anne-Sophie Carret

3 joint publications

Thomas W Flaig

3 joint publications

Jonathan E Rosenberg

2 joint publications

Patricia S Li

2 joint publications

Hala T Borno

Frequent Collaborators

3 joint publications

Lawrence Fong

3 joint publications

Matthew I Milowsky

3 joint publications

Christopher J Hoimes

3 joint publications

Daniel P Petrylak

Top Related Videos

Single-cell Gene Expression Profiling Using FACS and qPCR with Internal Standards
10:50

Single-cell Gene Expression Profiling Using FACS and qPCR with Internal Standards

Published on : Feb 25, 2017

16.4K
Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on : Nov 06, 2014

24.2K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

4.9K
See more related videos

Top Related Videos

Single-cell Gene Expression Profiling Using FACS and qPCR with Internal Standards
10:50

Single-cell Gene Expression Profiling Using FACS and qPCR with Internal Standards

Published on : Feb 25, 2017

16.4K
Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on : Nov 06, 2014

24.2K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

4.9K
See more related videos